Study Comparing Iberdomide and Lenalidomide Maintenance Therapy After Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Patients

Sponsor: Bristol-Myers Squibb

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05827016

Provider View

This clinical trial is evaluating whether iberdomide or lenalidomide is more effective as a maintenance therapy for patients with newly diagnosed multiple myeloma who have undergone a stem cell transplant.

Patient Parameters

Program Overview

The goal of this study is to determine which maintenance therapy, iberdomide or lenalidomide, is more effective in helping patients with newly diagnosed multiple myeloma maintain their health after receiving an autologous stem cell transplant. This study will help doctors understand which treatment option provides better outcomes for patients in maintaining remission and improving quality of life after the transplant.

Eligibility Criteria

Inclusion Criteria

  • Confirmed diagnosis of symptomatic multiple myeloma (MM).
  • Eastern Cooperative Oncology Group performance status (ECOG) score of 0, 1, or 2.
  • Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory (IMiD) [eg, bortezomib thalidomide and dexamethasone (VTd), lenalidomide, bortezomib and dexamethasone (RVd)] with or without a CD38 monoclonal antibody, daratumumab + bortezomib/thalidomide/dexamethasone [D-VTd] and daratumumab + bortezomib/ lenalidomide/dexamethasone [D-VRd]), or VCd / daratumumab + bortezomib/cyclophosphamide/dexamethasone [D-VCd], and followed by a single or tandem autologous stem cell transplantation (ASCT). Post-stem cell transplant consolidation is permitted.
  • Participants within 12 months (single transplant) or 15 months (tandem transplant) from initiation of induction therapy who achieved at least a partial response (PR) after autologous stem cell transplantation (ASCT) with or without consolidation, according to International Myeloma Working Group (IMWG 2016) criteria.

Exclusion Criteria

  • Progressive disease or clinical relapse (as defined by IMWG response criteria) following ASCT with or without consolidation or is not responsive to primary therapy.
  • Smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma.
  • Known central nervous system/meningeal involvement of MM.
  • Prior history of malignancies, other than MM, unless the participant has been free of the disease for ≥ 5 years.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.